文献速递药物不良反应与药物警戒

肥胖对皮下和肌内注射给药与吸收的影响

Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

本文讨论肥胖对皮下(SC)和肌内(IM)注射部位药物给药与吸收的潜在影响。肥胖可通过改变皮下组织组成和深度,或因针头长度不当导致IM药物误入皮下组织,从而影响药物吸收速率和程度及不良反应。随着越来越多生物治疗药物经SC注射获批,肥胖患者用药吸收问题将更突出,需研究辅助剂量决策。

要点

  • 肥胖改变皮下组织组成和深度,可能影响SC和IM药物的吸收速率与程度。
  • 针头长度不当可致IM药物误入皮下组织,影响吸收并增加不良反应风险。
  • SC注射相关不良反应包括肉芽肿、脂肪坏死和钙化,IM注射可致坐骨神经损伤等。

核心结论

  • 肥胖可能通过改变皮下组织组成和深度或针头长度不当影响SC和IM药物的吸收及不良反应。
  • 随着更多生物治疗药物经SC注射获批,肥胖患者药物吸收问题将更突出,需针对性研究辅助剂量决策。

研究设计与样本

  • 本文为综述性文章,讨论肥胖对SC和IM注射给药与吸收的潜在影响。

主要发现

  • SC给药适用于胰岛素等需较慢持续应答的产品,IM给药通常适用于疫苗等需较快吸收以产生较快抗体应答的产品。
  • 肥胖可能影响SC或IM途径给药药物的吸收速率和程度以及不良反应。
  • IM注射于臀部外上象限可致坐骨神经损伤,注射过深可致骨挫伤或罕见骨坏死。
  • SC注射相关不良反应包括肉芽肿、脂肪坏死和钙化。

临床怎么用

  • 选择SC或IM注射途径时应考虑具体药物特性及肥胖对吸收的潜在影响。
  • IM注射时需注意针头长度以避免药物误入皮下组织,并注意注射部位以降低神经损伤等风险。

局限性

  • 本文为综述性文章,未报告原始研究数据或具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To discuss the potential implications of obesity for drug administration and absorption from subcutaneous (SC) and intramuscular (IM) injection sites. SUMMARY: The SC and IM routes are useful for the parenteral administration of medications to optimize pharmacokinetic properties such as time to onset and duration of effect, for cost considerations, or for ease of administration, such as when intravenous access is unavailable. The choice of SC or IM injection depends on the specific medication, with SC administration preferred for products such as insulin where a slower and more sustained response is desirable, while IM administration is usually preferred for products such as vaccines where more rapid absorption leads to a more rapid antibody response. Obesity has the potential to influence the rate and extent of absorption, as well as adverse effects, of medications administered by the SC or IM route through changes in SC tissue composition and depth or by inadvertent administration of IM medications into SC tissue because of improper needle length. Potential adverse effects associated with IM or SC injections in addition to pain, bruising, and hematoma formation include sciatic nerve injury, particularly with IM injection in the upper outer quadrant of the buttock; bone contusion or rarely osteonecrosis if the IM injection is excessively deep; and granulomas, fat necrosis, and calcification with SC injection. CONCLUSION: Issues related to medication absorption in obese patients are likely to become more prominent in the future with increasing approvals of a wide range of biotherapeutic agents administered by SC injection. Studies should be directed toward these and other agents to assist with dosing decisions in this challenging population.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Erstad BL, Barletta JF. Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer. Am J Health Syst Pharm. 2022. PMID: 35176754. doi:10.1093/ajhp/zxac058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。